Home » News » Awards & Advancement » Axcan & Eurand change to Aptalis

Axcan & Eurand change to Aptalis

Friday, May 6, 2011

Axcan Intermediate Holdings has changed its name to Aptalis Pharma. The rebranding follows the recently completed combination of two specialty pharma companies focused on gastrointestinal diseases: Axcan and Eurand.

Aptalis currently markets several products around the world and has several compounds in various stages of development targeting unmet medical needs. The pipeline includes a recent acquisition, Aeroquin from Mpex Pharmaceuticals, currently in phase III clinical trials for the treatment of pulmonary infections in patients with cystic fibrosis.


Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!